The invention relates to compounds of the general formula
1
wherein
(R
1
)
n
is independently from from each other halogen, lower alkyl or lower alkoxy;
R
2
is hydrogen, lower alkyl, lower halogen-alkyl, —(CH
2
)
m
—OH, —(CH
2
)
m
—NR
2
, —(CH
2
)
m
O-lower alkyl, —(CH
2
)
m
—C(O)—NR
2
, or is —(CH
2
)
m
-6-membered heteroaryl, optionally substituted by one or more lower alkoxy, —(CH
2
)
m
-5 or 6-membered not aromatic heterocyclyl, optionally substituted by hydroxy or lower alkyl;
R is hydrogen or lower alkyl and may be the same or different in case of R
2
;
n is 0, 1, or 2;
m is 0, 1, 2, 3 or 4;
and pharmaceutically acceptable acid addition salts thereof. These compounds have a good affinity to the NK-1 receptor and they are therefore suitable for the treatment of diseases, related to this receptor.
该发明涉及一般式1的化合物,其中(R1)独立地为卤素、较低的烷基或较低的烷
氧基;R2为
氢、较低的烷基、较低的卤代烷基、—(
CH2)m—OH、—( )m—NR2、—( )mO-较低的烷基、—( )m—C(O)—NR2,或为—( )m-6-成员杂环芳基,可选择地被一个或多个较低的烷
氧基取代,—( )m-5或6-成员非芳香杂
环烷基,可选择地被羟基或较低的烷基取代;R为
氢或较低的烷基,在R2的情况下可能相同或不同;n为0、1或2;m为0、1、2、3或4;以及其药学上可接受的酸盐。这些化合物对NK-1受体具有良好的亲和力,因此它们适用于治疗与该受体相关的疾病。